Lymphoplasmacytic Lymphoma Completed Phase 1 / 2 Trials for Entospletinib (DB12121)

IndicationStatusPhase
DBCOND0031072 (Lymphoplasmacytic Lymphoma)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03010358Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin LymphomaTreatment